Molecular Diagnostics Billing Services That Get Every Claim Reimbursed

Molecular diagnostics claims are denied at nearly triple the rate of routine lab tests, and the reasons rarely show up in a standard denial report; a missing DEX Z-Code, a PLA code billed without its matching identifier, an unlisted 81479 claim with no gene named in the narrative field, a prior authorization gap on a $3,000 NGS panel. TransLabs’ molecular billing specialists close those gaps with a 98% clean claims rate and 35% faster A/R, with measurable recovery in the first 90 days.
Molecular Diagnostics Billing Services
0%
Client Retention Rate
0%
First-Pass Claim Rate
0%
Avg. Revenue Growth
0%
Avg. Denial Reduction

Why Molecular Diagnostics Laboratories Lose Revenue Every Single Day

Molecular and genomic testing isn’t billed like chemistry or hematology, and it certainly isn’t billed like a physician office visit. Z-Code identifiers, PLA codes, Tier 1 and Tier 2 stacking rules, and payer-specific prior authorization thresholds create a coding and compliance layer that most billing companies were never built to handle. The losses rarely show up as one big denial; they show up as a slow, steady erosion across hundreds of claims a month, until a payer audit forces the issue.

The Five Revenue Leaks Most Molecular Labs Don't Know They Have

Missing or Invalid DEX Z-Code Identifiers

PLA and Unlisted Code Mismatches

Tier 2 and Panel Stacking Violations

Prior Authorization Gaps on High-Cost Panels

Diagnosis-to-Test Linkage Failures

Molecular Diagnostics Billing Services

Every Molecular Testing Discipline, Billed Correctly; From Single-Gene Assays to Whole-Genome Sequencing

From a single Tier 1 BRCA1 analysis to a 500-gene comprehensive genomic profiling panel, our molecular billing coders hold AAPC and AHIMA credentials and stay current on MolDX policy updates, PLA code releases, and payer-specific LCDs across every molecular and genomic testing discipline.

Oncology & Tumor Molecular Profiling

CPT 81162–81479, MAAA 81490–81599, PLA 0001U–0999U

Single-gene and multi-gene solid tumor panels (EGFR 81235, KRAS 81275, BRAF 81210, ALK rearrangement testing), myeloid and lymphoid mutation panels, comprehensive genomic profiling panels, measurable residual disease (MRD) assays, and companion diagnostic testing tied to targeted therapy selection.

Key Billing Consideration

Comprehensive genomic profiling panels are billed under a single PLA or unlisted code that already reflects every analyte in the panel; billing individual gene components on top of the panel code is a stacking violation and a top MolDX audit trigger.

Hereditary Cancer & Germline Genetic Testing

CPT 81162–81217, 81432–81433, MAAA 81436–81437

BRCA1/BRCA2 full gene sequence analysis (81162), Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2), multi-gene hereditary cancer panels (81432, 81433), PALB2, APC, and other high- and moderate-penetrance cancer susceptibility genes.

Key Billing Consideration

Diagnostic testing and unaffected at-risk family member testing require different ICD-10 code families under most payer policies; using a personal-history diagnosis code for a predisposition test on an unaffected relative is one of the most common denial triggers in this category.

Pharmacogenomics (PGx) Testing

CPT 81225–81355, PLA codes for multi-gene panels

CYP2D6, CYP2C19, CYP2C9, VKORC1, and SLCO1B1 single-gene assays, plus multi-gene PGx panels used to guide psychiatric medication selection, cardiovascular drug dosing, and pain management prescribing.

Key Billing Consideration

Medicare LCDs limit PGx coverage to specific drug classes and documented diagnosis linkage, and many commercial payers still classify broad multi-gene PGx panels as investigational; predetermination before testing prevents an avoidable 100% denial.

Next-Generation Sequencing & Genomic Sequencing Procedures

CPT 81410–81471

Hereditary cardiovascular disease panels (81439), hereditary neurological disorder panels (81448), exome sequencing (81415, 81416), genome sequencing (81425, 81426), and mitochondrial genome analysis (81440, 81441).

Key Billing Consideration

Genomic Sequencing Procedure codes already bundle the full multi-gene analysis into one code; billing separate Tier 1 codes for genes already captured inside that panel is unbundling and is routinely recouped on post-payment review.

Molecular Infectious Disease & NAAT Testing

CPT 87470–87801, PLA codes for syndromic panels

Respiratory pathogen PCR panels, gastrointestinal pathogen panels, STI NAAT testing (chlamydia/gonorrhea 87491/87591), HCV and HIV viral load quantification (87522, 87536), and C. difficile toxin gene PCR (87493).

Key Billing Consideration

Syndromic panel codes already bundle multiple individual targets; billing separate target-specific codes alongside the panel code is one of the most frequently cited findings in molecular infectious disease post-payment audits.

Prenatal, Reproductive & Carrier Screening

CPT 81228–81229, 81243–81244, 81420–81422, 81507

Non-invasive prenatal testing (NIPT, 81420), expanded carrier screening panels, fragile X testing (81243, 81244), and chromosomal microarray for prenatal indications.

Key Billing Consideration

Coverage for NIPT and expanded carrier panels hinges on documented risk factors such as maternal age or family history; billing without that documentation attached is a leading cause of denial in reproductive genetic testing.

Cytogenomics & Chromosomal Microarray

CPT 81228–81229, 81349, 88230–88275

Chromosomal microarray for constitutional and oncology indications, FISH probe studies (88271–88275), and conventional chromosome analysis and karyotyping (88230–88264).

Key Billing Consideration

Technical and professional component splits for cytogenetic interpretation are frequently miscoded, and FISH billing must reflect the exact number of probes hybridized rather than the panel's marketed name.

Proprietary Laboratory Analyses (PLA) Codes

CPT 0001U–0999U

Lab-specific and manufacturer-specific assays, including many multi-analyte NGS oncology panels, multi-gene PGx panels, and MRD assays that have been assigned their own dedicated PLA code by the AMA.

Key Billing Consideration

A PLA code applies only to the exact test version it was issued for; billing it without the matching DEX Z-Code identifier, or for a modified assay, is one of the most common MolDX-driven rejections we see.

Our Laboratory RCM Services

TransLabs’ specialized RCM services are built exclusively for labs, addressing the unique challenges that generalist billers miss. We provide end-to-end revenue cycle solutions designed specifically to turn laboratory complexity into profitability.

Proficient Across Multiple LIS & EHRs to Simplify Your
Laboratory Management

ChartLogic
Collaborate md
Greenway health
Haemonetics
jane
cgm Labdaq
Modmed
open emr
Harris Data Integrity Solutions
siemens healthineers
Tebra
Oracle Health
Confience
Power path
Benchmark solutions
Xifin
Psyche Systems
veradigm
Turemed Lis
Telcor
Practice pro
novo path
Nextgen Healthcare
Next tech
meditech
Advanced data systems corporation
Logilab
Labware
Lab vantage
labs os
Epic
Dr Chrono
dendi
Corepoint
clinisys
Care Cloud
apex healthware
clinisys copathplus
Advanced md
softlab
athenaone

Serving Labs Across The United States

TransLabs provides expert RCM services to clinical laboratories in all 50 states, delivering the same exceptional results whether you’re a community hospital lab or a large reference facility. We bring specialized lab billing expertise to facilities nationwide, combining remote efficiency with hands-on partnership.

Medicare Part B and MolDX Compliance for Molecular Diagnostics

Molecular diagnostics billing under Medicare Part B carries a compliance layer that goes beyond standard laboratory billing. The MolDX Program, DEX Z-Code requirements, PLA code governance, and stacking restrictions on Tier 2 and NGS codes create a regulatory environment that catches even experienced billing teams off guard.
MolDX Program & DEX Z-Code Identifiers

Palmetto GBA's MolDX Program requires a unique DEX Z-Code identifier on every in-scope molecular diagnostic claim, reported alongside the CPT or PLA code. TransLabs registers and maintains your lab's Z-Codes in the DEX Diagnostics Exchange and validates the correct identifier against every claim before it's submitted, not just for the tests you run most often.

Local Coverage Determinations for Molecular & Genetic Tests

Each Medicare Administrative Contractor maintains its own LCDs specifying which diagnoses support coverage for specific molecular and genetic tests, and these policies frequently distinguish diagnostic testing from screening or predisposition testing. TransLabs maintains live LCD databases by MAC and validates ICD-10 linkage before submission.

PLA Code & Stacking Compliance

CMS and commercial payers actively monitor for inappropriate stacking of Tier 2 and unlisted molecular pathology codes, and for PLA codes billed without their required identifiers. TransLabs cross-references every claim against current AMA PLA code releases and CMS stacking guidance before it leaves our system.

Prior Authorization & Medical Necessity Documentation

High-cost NGS panels, hereditary cancer testing, and expanded carrier screens frequently require prior authorization or detailed medical necessity documentation before specimen collection. TransLabs builds these checks into your front-end intake workflow so authorization is confirmed before testing begins, not after a denial arrives.

PAMA Reporting Requirements

Labs meeting the applicable laboratory definition under the Protecting Access to Medicare Act carry mandatory private payer data reporting obligations during designated collection periods, and molecular and genomic tests are frequently subject to this reporting. TransLabs tracks your lab's PAMA obligations throughout the year.

OIG Work Plan & Program Integrity Monitoring

Genetic and molecular testing has drawn sustained attention from CMS and the Office of Inspector General in recent years, including enforcement actions tied to medically unnecessary panels and improper billing arrangements. TransLabs builds compliance protocols around current program integrity priorities so your lab's billing patterns hold up under scrutiny.

We Bill Only for Diagnostic Laboratories and Molecular Testing Is Where That Focus Matters Most

Most billing companies treat molecular diagnostics as an add-on to chemistry or pathology billing. It isn’t. Molecular and genomic testing has its own code families, Z-Code and PLA governance, and prior authorization landscape. TransLabs built a dedicated molecular team; coders and appeal writers who work exclusively in molecular claims, not generalists handling a mixed caseload.

Molecular-Exclusive Specialization

Our molecular billing coders don’t split time across disciplines; molecular and genomic billing only.

98% First-Pass Clean Claims Rate

98%+ clean claims rate across all lab clients with fewer denials, faster payments, stronger cash flow.

Active DEX Z-Code & MolDX Management

We register and maintain your DEX Z-Codes directly; no more denials from identifier mismatches.

High-Complexity Claims Architecture

We validate Tier 1, Tier 2, PLA, and GSP stacking rules on every claim, at volume, without slowing turnaround.

No Long-Term Contracts

Month-to-month, results-based partnership with measurable improvement in 90 days, no exit fees, just 30 days’ notice.

Transparent Reporting

Monthly dashboards with full visibility of clean claims rate, denial trends, A/R aging, and root cause analysis, no surprises.

Get Your Molecular Diagnostics Custom Revenue Recovery Plan

Schedule a call with our molecular billing specialist. We’ll review your Z-Code registration, PLA coding accuracy, prior authorization workflow, and A/R days.

What Our Clients Say?

Linda Hutchinson
Linda Hutchinson
Laboratory Director
Our NGS panel denials dropped from 32% to under 6% within three months. TransLabs' expertise with molecular tier codes, prior authorization management, and LCD compliance has been invaluable. They understand the nuances of genetic testing billing that our previous vendor completely missed.
Peter Wozniak
Peter Wozniak
Pathologist & Laboratory Owner
We've worked with three other billing companies over the years. TransLabs is the only one that truly understands complex surgical pathology coding, immunohistochemistry billing, and the nuances of TC/PC modifiers. Clean claims rate improved to 99%, and our dermatopathology reimbursement increased 27%.
James Patton
James Patton
Cytogenetics Laboratory Manager
Before TransLabs, our FISH and karyotype claims were a constant struggle with denials and underpayments. Their coders actually understand probe configurations, complexity levels, and when to use 88271 versus 88275. Our cytogenetics revenue increased 34% in the first year.

Book Consultation Today!

Stop Leaving Complex Claims on the Table

Join the growing number of molecular and genomic diagnostic laboratories, from single-site reference labs to multi-site oncology networks, that trust TransLabs, the laboratory billing company built for high-complexity testing. Start with our complimentary molecular claims audit. Our specialists will review your Z-Code registration, PLA coding accuracy, and denial trends to show you exactly what’s recoverable.

Dedicated molecular billing specialist assigned to your lab

Complimentary 12-month claims audit across Medicare, Medicaid, and commercial payers

Uncover your top 3 revenue leaks (Z-Code gaps, stacking errors, prior auth denials)

Custom strategy tailored to your test menu and LIS/genomics platform

Live in 24 hours with no contracts and no upfront fees

Pay only a percentage of what we collect for you

Frequently Asked Questions

What is molecular diagnostics billing and how is it different from routine clinical lab billing?

Molecular diagnostics billing covers genetic and genomic testing claims using Tier 1, Tier 2, GSP, and PLA codes (81161–81599, 0001U–0999U) instead of standard chemistry or hematology codes. These claims require a DEX Z-Code identifier under the MolDX Program, face stricter prior authorization requirements, and carry payer-specific stacking and medical necessity rules that routine lab billing doesn’t.
Typically 6–9% of net collections, slightly higher than routine lab billing given the added complexity of PLA coding, Z-Code management, and prior authorization work. TransLabs charges transparently with no setup fees or long-term contracts, and the revenue recovered from correcting stacking errors and Z-Code gaps usually offsets the fee within the first 60 days.
A DEX Z-Code is a unique identifier issued through Palmetto GBA’s Diagnostics Exchange that tells a payer exactly which molecular test was performed. Most MolDX-jurisdiction Medicare claims, and a growing number of commercial payers, will deny a molecular diagnostic claim outright if it’s missing or mismatched.
Tier 1 codes (81161, 81200–81383) cover well-established, commonly performed single-gene tests. Tier 2 codes (81400–81408) are stacked by complexity level and used for less common analytes without a dedicated Tier 1 code. PLA codes (0001U–0999U) are lab- or manufacturer-specific codes issued for a single proprietary test version, and they can’t be substituted with a generic code once one exists.
We verify coverage and complete prior authorization before specimen processing begins for any test with a payer-specific authorization requirement, including hereditary cancer panels, expanded carrier screens, and comprehensive genomic profiling. This prevents the four-figure write-offs that come from testing first and finding out about the authorization requirement later.
Industry-wide, molecular and genomic claims are denied at meaningfully higher rates than routine lab tests, often in the 15–25% range for labs without dedicated molecular billing expertise. TransLabs clients typically operate in the single digits. Common denial drivers include missing Z-Codes, Tier 2/PLA stacking errors, and diagnosis-to-test mismatches.
Yes. We’ve integrated with major LIS and genomics informatics platforms, including systems used for NGS workflow management and variant reporting. Integration includes automated charge capture, CPT/PLA mapping, and Z-Code linkage, typically completed within two to three weeks given the added complexity of molecular test menus.
Yes, Medicare Part B, Medicaid in all 50 states, and commercial carriers including UnitedHealthcare, Aetna, and BCBS plans. We monitor MolDX policy updates and commercial Z-Code requirement rollouts monthly, since several major payers have added Z-Code mandates in just the past two years.

Your Trusted Lab Billing Partner

Book Your Free Consultation

Book Consultation Today!

Book Consultation Today!